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BACKGROUND: Cytokeratins (CKs) are structural marker proteins specific for epithelial cells. However, recent studies indicate their
involvement in cancer progression.
METHODS: We evaluated CK18 and its filament partner, CK8 expression, by immunohistochemistry in 210 resected specimens from
patients with oesophageal squamous cell carcinoma (OSCC). We also analysed the relationship between their expression and
various clinicopathological parameters including prognosis.
RESULTS: Neither CK18 nor CK8 was expressed in non-cancerous squamous epithelium whereas proper oesophageal glands
expressed both CKs. Ninety (42.9%) tumours were CK18 positive and 85 (40.5%) CK8 positive, and the concordance rate for
immunohistochemical classification for CK18 and CK8 was 82.4%. CK18 expression correlated with poorly differentiated tumours,
use of neo-adjuvant chemotherapy, and advanced stage. Prognosis of patients with CK18-positive tumours was poorer than that of
patients with negative OSCC (Po0.001). A similar trend was noted for CK8 expression. Multivariate analysis identified pT
(P¼0.020), pN number (P¼0.001), and CK18 expression (P¼0.004) as independent prognostic factors. CK18 expression in 83
pretreatment biopsy specimens was detected in 47 cases (56.6%) and also correlated with prognosis (P¼0.045).
CONCLUSION: CK18/CK8 expression correlated with progression of OSCC. The significant correlation with prognosis and stable
expression in biopsy specimen suggest usefulness of CK18 in selection of treatment strategies for OSCC.
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Oesophageal squamous cell carcinoma (OSCC), the major
histopathological form in East Asian countries, is one of the most
lethal malignancies of the digestive tract and frequently diagnosed
at advanced stage (Shimada et al, 2003). Although surgical
resection is one of the most reliable treatments in OSCC, disease
recurrence often occurs even after curative resection. Earlier
reports suggested the usefulness of preoperative chemotherapy/
chemoradiotherapy and postoperative chemotherapy in OSCC
(Fiorica et al, 2004; Ando et al, 2003; Kaklamanos et al, 2003;
Tepper et al, 2008). For effective indication of these therapeutic
modalities, it is necessary to identify those patients with poor
prognosis who are best candidates for these therapies. So far,
pathological findings based on examination of resected specimen
are the most reliable information for prediction of clinical
outcome, however, the predictive values of these variables remain
unsatisfactory and not available for preoperative setting. There-
fore, there is a need for the development of novel biological
markers that can accurately distinguish high-risk population of
recurrent disease by combining conventional TNM classification
(Sobin, 2002), for more appropriate treatment strategy.
Cytokeratin (CK), an intermediate filament observed mainly in
epithelial cells, is an essential cytoskeletal component involved in
fixation of the nucleus and maintenance of cell morphology.
The cytoskeleton of epithelia is formed by 20 subtypes of CKs
whose expression depends primarily on epithelial cell type and
degree of differentiation (Chu and Weiss, 2002a). These CKs are
divided into two groups; type I (acidic, CK9–20) and type II
(neutral–basic, CK1–8) gene families (Moll et al, 1982; Hesse et al,
2001). In non-cancerous tissue, CK18 and its co-expressed
complementary subunit, CK8, are commonly expressed in normal
glandular epithelia, transitional cell epithelium, and hepatocyte,
but not in squamous stratified epithelium (Debus et al, 1984;
Schaafsma et al, 1990; Trask et al, 1990; Schussler et al, 1992).
Interestingly, in cancerous tissue, adenocarcinomas, such as
human breast or colorectal carcinoma frequently show reduced
CK8/18 expression, which correlates with tumour progression and
poor outcome (Woelfle et al, 2004; Knosel et al, 2006). On the
other hand, CK8/18 expression is upregulated in head and neck
carcinoma (Xu et al, 1995; Gires et al, 2006), oral cavity carcinoma
(Fillies et al, 2006), and transitional cell carcinoma of the urinary
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stract (Schaafsma et al, 1990; Southgate et al, 1999), and is
associated with unfavourable prognosis (Fillies et al, 2006).
In vitro analysis demonstrated the malignant role of CK8/18
expression, indicating that various CK8/18-overexpressing cell
lines, such as human lung adenocarcinoma (Chu et al, 1997),
human melanoma cells (Chu et al, 1996), and mouse L cells (Chu
et al, 1993), have higher migratory/invasive abilities compared
with the control.
Apart from CK8/18, earlier reports described loss of CK7 and
acquisition of CK20 in colorectal carcinoma (Park et al, 2002),
acquisition of CK7, and loss of CK20 in gastric carcinoma
(Park et al, 2002; Kim et al, 2004), and acquisition of CK1, 5, 6,
8, 19 in squamous cell carcinoma (Xu et al, 1995; Chu and Weiss,
2002a,b; Ikeda et al, 2008). Thus, it seems that CK expression in
epithelial tissues can change with differentiation or malignant
transformation (Hendrix et al, 1996) in an organ-specific manner
(Kurokawa et al, 2006). Although earlier reports indicated
upregulation of CK8/18 in OSCC during the pre-cancerous and
cancerous stages (Grace et al, 1985; Lam et al, 1995; Takahashi
et al, 1995; Viaene and Baert, 1995; Cintorino et al, 2001), to our
knowledge, their role in prognosis has not been evaluated. Here,
we assessed CK18 and CK8 expression levels in OSCC by using a
series of 210 resected specimens. Furthermore, considering the
clinical application of these CKs in the future, we also examined
the expression levels of CK18 in biopsy specimens obtained by
endoscopy.
PATIENTS AND METHODS
Patients and treatments
This retrospective study involved 210 patients with thoracic
oesophageal cancer who underwent surgical resection in our
hospital from 1998 to 2007. All 210 patients were confirmed to
have OSCC by histopathological examination of endoscopic biopsy
and considered suitable for surgery based on preoperative
assessment. They included 23 females and 187 males, aged between
38 and 82 (median, 63.1 years). Table 1 lists patient characteristics.
Of the total, 110 patients with cN1 received neo-adjuvant
chemotherapy (NACT), which consisted of two courses of
5-fluorouracil (5-FU), cisplatin (CDDP), and adriamycin (ADM)
(Akita et al, 2006; Yano et al, 2006; Matsuyama et al, 2007; Makino
et al, 2008). Curative resection (R0), that is, oesophagectomy with
two- or three-field lymphadenectomy, was performed in 199
patients (94.8%), whereas non-curative resection (R2) was carried
out in the remaining 11 patients (5.2%); these patients were
excluded from the survival analysis. None of the patients died of
postoperative complications. Sixty-five patients with multiple
metastatic lymph nodes in the surgical specimen received
docetaxel or CDDP plus 5-FU postoperatively (Ando et al, 2003).
In our hospital, patients with OSCCs that invade the airway or
major blood vessels or accompanied by visceral metastasis are not
indicated for surgery and therefore receive chemoradiotherapy or
chemotherapy alone.
After surgery, the patients were surveyed every 3 months by
physical examination and serum tumour markers, every 6 months
by CT scan and abdominal ultrasonography, and every year by
endoscopy until tumour recurrence was evident. Patients with
tumour recurrence received chemotherapy or chemoradiotherapy,
as long as their systemic condition permitted. The mean
overall survival (OS) was 34.9 months and mean disease-free
survival (DFS) was 22.2 months. The mean follow-up period
after surgery was 38.8 months. This study was approved by the
Human Ethics Review Committee of Osaka University School of
Medicine and a signed consent form was obtained from each
subject.
Quantitative reverse transcription polymerase chain
reaction analysis
Total RNA was extracted from fresh frozen tissue of resected
tumours in 21 out of total 210 OSCCs using TRIzol Reagent
(Invitrogen, Carlsbad, CA, USA). Complementary DNA (cDNA)
was generated from 1mg RNA in a final volume of 20ml, containing
oligo-(dT)15 primer, avian myeloblastosis virus transcriptase, with
reverse transcription (RT) system (Promega, Madison, WI, USA).
Polymerase chain reaction (PCR) analysis was performed by using
LightCycler, a real-time monitoring thermal cycler. Polymerase
chain reaction reaction mixture was prepared containing 2mlo f
cDNA template, 3mmoll
 1 MgCl2, 250nmoll
 1 of primer pairs,
using LightCycler FastStart DNA Master SYBR Green I (Roche
Diagnostics, Mannheim, Germany). The amount of each transcript
was normalised against the expression of the housekeeping gene,
glydecaldehyde-3-phosphate-dehydrogenase (GAPDH). Standard
curve was constructed with 10-fold serial dilutions of cDNA
obtained from non-cancerous oesophageal mucosal cell layers of
tissue samples from 10 cases as a standard mixture. The sequences
of PCR primers for GAPDH, CK18, and CK8 were as follows:
forward primer 50-CAACTACATGGTTTACATGTTC-30, reverse
primer 50-GCCAGTGGACTCCACGAC-30 used for amplification
of GAPDH, forward primer 50-ATCTTGGTGATGCCTTGGAC-30,
reverse primer 50-CCTGCTTCTGCTGGCTTAAT-30 for CK18, and
forward primer 50-TAGCACTGGGAACAGGAGA-30, reverse pri-
mer 50-TTTGACATTGGCAGAGCTA-30 for CK8. The PCR cycling
condition was set as follows: an initial denaturing step at 951C for
10min and 40 cycles at 951C for 15s, 581C for 10s, and 721C for
25s. The relative amount of cDNA in each sample was measured
by interpolation on the standard curve, and then the relative ratio
of CK18/GAPDH mRNA or CK8/GAPDH mRNA expression in log2
scale was calculated for each OSCC sample.
Immunohistochemical analysis
The amounts of CK18 and CK8 proteins in the tissues were
examined by immunohistochemical staining of formalin-fixed and
paraffin-embedded serial sections. One representative slide with
the deepest tumour invasion was selected from each patient and
subjected to immunohistochemistry using the streptavidin–
peroxidase method. Briefly, after deparaffinisation in xylene and
dehydration in graded ethanol, endogenous peroxidase activity
was blocked by incubation with 30mll
 1 hydrogen peroxide for
20min. Then tissue sections were heated for 40min at 951Ci n
citrate buffer (0.05moll
 1, pH 6.0) for antigen retrieval. After
incubation with mouse monoclonal primary antibody DO10
(Bartek et al, 1991) (Novocastra, Newcastle, UK, dilution 1:40)
Table 1 Patients characteristics (n¼210)
Age (years)
a 63.1 (38–82)
Gender (males/females) 187/23
Histopathology (well/mod/poor) 48/107/55
Location (upper/middle/lower) 27/101/82
Neo-adjuvant chemotherapy (yes/no) 110/100
cT (0/1/2/3/4) 0/28/63/94/25
pT (0/1/2/3/4) 0/39/35/120/16
cN (N0/N1/M1lym) 67/143/46
pN (N0/N1/M1lym) 61/149/51
Number of p (N0/1-3/4-7/8) 59/85/26/40
cStage (0/I/II/III/IV) 0/20/72/72/46
pStage (0/I/II/III/IV) 0/18/75/66/51
aData are average and (range). Well/mod/poor¼well, moderately, and poorly
differentiated squamous cell carcinoma; upper/middle/lower¼middle, lower, and
upper thoracic oesophagus. cT, cN, cStage (clinical classification); pN, pT, pStage
(pathological classification); and M1lym (distant lymph node metastasis) are based on
TNM classification.
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sfor CK18 and TS1 (Johansson et al, 1999) (Novocastra, dilution
1:200) for CK8 for 14h, the sections were stained by the labelled
streptavidin biotin method. Negative controls of immunohisto-
chemical reactions were performed by omitting the primary
antibody. Positive staining of normal oesophageal gland at the
non-cancerous area in the same section was used as an internal
positive control. Furthermore, CK18 immunoreactivity was
examined using the same antibody and methods in pretreated
fiberscopic biopsy samples obtained from 83 of the 210 patients.
The presence of CK18 or CK8 protein was judged ‘positive’ when
the proportion of immunohistochemically stained cells was more
than 50% of all observed cancer cells (Lam et al, 1995), or
otherwise ‘negative’. All slides were assessed by two observers
independently and then in conference in a blinded manner without
any prior knowledge of the clinicopathological parameters.
Characteristically, immunostaining of CK family of proteins yields
clearly recognised tumour cells with sufficient intensity and
frequency, with little or no background or non-specific staining.
Therefore, the judgment of immunostaining was always consistent
between the two observers and the results were the same on
different cut-off lines around 10–50% of the proportion of
immunohistochemically stained cells.
Western blot analysis
Western blot analysis was performed to confirm the specificity of
CK18 and CK8 antibodies (Miyata et al, 2001). Briefly, the protein
extracted from tissue samples (20mg), MCF7 whole cell lysates
(0.5mg) and recombinant protein of each CK18 and CK8 (ProSpec-
Tany Technogene, Rehovot, Israel) (0.1mg) were separated using
7.5% polyacrylamide gel electrophoresis, followed by electroblot-
ting onto a polyvinylidene difluoride membrane. The membrane
was incubated with the primary antibodies at appropriate
concentrations (anti-CK18 1:200 dilution, anti-CK8 1:500 for
12h at 41C, and anti-actin 1:2000 for 1h at room temperature).
Protein bands were detected using the Amersham-enhanced
chemiluminescence detection system (Amersham Biosciences
Corp., Piscataway, NJ, USA).
Statistical analysis
Data are expressed as mean±s.d. Differences in continuous
parameters between two groups classified by CK18 or CK8 protein
expression were evaluated by the Mann–Whitney’s U test.
Correlations between CK18 expression on immunohistochemistry
and various clinicopathological parameters were evaluated by the
w
2 test and Fisher’s exact probability test. Regression analysis was
used to determine the correlation between CK18 and CK8 gene
expressions using Pearson’s correlation coefficient (R value).
Prognostic variables were assessed by the log-lank test, and DFS
and OS were analysed by the Kaplan–Meier test. Cox’s propor-
tional hazard regression model with stepwise comparison was used
to analyse the independent prognostic factor(s). All statistical
analyses were carried out using SPSS for Windows release 10
(SPSS, Inc, Chicago, IL, USA). A P-value of o0.05 was accepted as
statistically significant.
RESULTS
Cytokeratins 18 and 8 expression in oesophageal squamous
cell carcinoma
Non-cancerous squamous epithelium showed no immunohisto-
chemical staining for both CK18 and CK8, but adjacent proper
oesophageal glands always showed strong immunostaining for
both, which served as an internal positive control (Figure 1A
and B). All 210 samples, including cancer and non-cancerous
lesions in the same section, were evaluated for CK18 and CK8
protein expression by immunohistochemical analysis (IHC),
respectively. Positive CK18 expression was identified in 90
(42.9%) cases, and the staining was mainly observed in the
cytoplasm of tumour cells. The remaining 120 (57.1%) cases were
negative (Figure 1C and D). Furthermore, 85 (40.5%) cases showed
positive immunostaining for CK8 in the cytoplasm of tumour cells,
whereas 125 (59.5%) were negative (Figure 1E and F). The positive
Figure 1 CK18/CK8 expression by immunohistochemical staining.
(A) Normal squamous epithelium was negative for CK18 (magnification
 100). (B) Normal oesophageal glands showed positive staining for
CK18, which was used as an internal control (magnification  200). (C, E)
Representative examples of CK18-positive (C) and CK8-positive (E)
oesophageal squamous cell carcinomas, which showed staining in more
than 10% of all tumour cells (magnification C, E  200). (D, F) CK18-
negative (D) and CK8-negative (F)- oesophageal squamous cell carcinomas
showed almost no appreciable staining of tumour cells (magnification D
 20, F  40). (G, H) CK18 (G) and CK8 (H) immunostaining in intra-
epithelial neoplasia (magnification G  200, H  100). (I) CK18-positive
oesophageal squamous cell carcinoma in a pretreatment biopsy specimen
(magnification  40).
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sstaining for CK18/8 was almost homogeneous at single cancer nest
and among different areas (surface, central, and deepest areas) of
the cancer lesion. There was a significant correlation between
CK18 and CK8 immunostaining (Po0.001); 69 (32.9%) patients
showed positive immunostaining for both CK18 and CK8, with
largely matching distribution, whereas 104 (49.5%) were negative
for both. On the other hand, 37 (17.6%) patients showed
discordant immunostaining, including CK18 positive and CK8
negative in 21 cases, and CK18 negative and CK8 positive in 16
(Table 2). Intra-epithelial neoplasia (dysplasia) was observed in 55
cases. Among them, CK18 and CK8 expressions were detected in
13 (23.6%) and 14 (25.5%) cases, respectively (Figure 1G and H).
Western blot analysis demonstrated strong expression of CK18
and CK8, with molecular weights of 45 and 52.5kDa, respectively,
in whole cell lysates of MCF7 and recombinant proteins of CK18
and CK8. In cancer tissue obtained from one representative patient
positive for both CK18 and CK8 expression by immunohisto-
chemistry, CK18 and CK8 were strongly expressed, but not in
normal squamous epithelial cells (Figure 2).
Quantitative RT–PCR analysis was performed in 21 representa-
tive cases to elucidate the mechanisms of gene transcription and
the relationship between protein and mRNA expression levels of
these molecules. It showed the expression level of CK18 mRNA in
CK18-positive tumours (n¼5) was significantly higher than that
in CK18-negative cases (n¼16) (1.78±0.92 vs  0.001±0.87,
P¼0.005). Similarly, the expression level of CK8 mRNA in CK8-
positive tumours (n¼6) was significantly higher than that in CK8-
negative cases (n¼15) (3.08±1.46 vs 0.84±1.75, P¼0.016)
(Figure 3). Regression analysis showed a significant correlation
between CK18 and CK8 mRNA expression (R¼0.822, R2¼0.675,
Po0.001).
Correlation between cytokeratins 18 and 8 expression and
clinicopathological parameters
Table 3 lists the correlations between CK18 and CK8 expression
and various clinicopathological parameters. In comparison with
Table 2 Correlation between CK18 and CK8 protein accumulation
examined by immunohistochemical staining
CK8
Positive Negative Total
CK18
Positive 69 21 90 (42.9%)
Negative 16 104 120 (57.1%)
Total 85 (40.5%) 125 (59.5%) 210 (100%)
Po0.0001 by Fisher’s exact test.
N CK8 CK18
45 kDa
52.5 kDa
Anti-CK8
T N Anti-CK18 CK8 CK18
52.5 kDa
45k Da
MCF7
T MCF7
Figure 2 CK18/CK8 expression by western blot analysis. Each CK18 and
CK8 expression was examined by western blot in oesophageal cancer
tissue (T) and normal squamous epithelium (N) obtained from the same
patient. Whole cell lysates of MCF7 and recombinant protein of each CK18
and CK8 were used as positive controls.
C
K
1
8
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
 
(
/
G
A
P
D
H
)
Positive
(n=5)
Negative
(n=16)
CK18 protein expression
P=0.0050
Positive
(n=6)
Negative
(n=15)
CK8 protein expression
–2
–1
0
1
2
3
4
5
P=0.0158
–1.5
–1
–0.5
0
0.5
1
1.5
2
2.5
3
3.5
C
K
8
 
g
e
n
e
 
e
x
p
r
e
s
s
i
o
n
 
(
/
G
A
P
D
H
)
Figure 3 Relationship between protein expression and mRNA expression
of CK18 and CK8. The relative ratio of CK18 mRNA expression in CK18-
positive tumours (n¼5) was significantly higher than in CK18-negative tumours
(n¼16). A similar trend was observed for CK8 mRNA expression in CK8-
positive (n¼6) and CK8-negative (n¼15) tumours. Data are mean±s.d.
Table 3 Correlation between CK18/CK8 and various clinicopathological
parameters
CK18 CK8
Positive Negative P Positive Negative P
Age
o65 55 61 0.1615 53 63 0.0922
465 35 59 32 62
Gender
Male 83 104 0.2654 77 110 0.6555
Female 7 16 8 15
Histopathology
Well 7 41 o0.0001 5 43 o0.0001
Mod, poor 83 79 80 82
Location
Upper 13 11 0.2758 14 10 0.0766
Middle, lower 77 109 71 115
Neo-adjuvant chemotherapy
Present 56 54 0.0175 52 58 0.0485
Absent 34 66 33 67
pT
T0–2 24 50 0.0287 29 45 0.8831
T3–4 66 70 56 80
Number of pN
o4 50 94 0.0005 51 93 0.0340
444 0 2 6 3 4 3 2
pStage
1 5 13 0.0045 8 10 0.6488
22 2 5 3 2 6 4 9
33 6 3 0 2 9 3 7
42 7 2 4 2 2 2 9
Well, mod, poor¼well, moderately, and poorly differentiated squamous cell
carcinoma; upper, middle, lower¼upper, middle, lower, and thoracic oesophagus.
pT, pN, pStage (pathological classification) based on TNM classification.
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sCK18-negative OSCCs, the proportion of CK18-positive tumours
was significantly higher among moderately poorly differentiated
OSCCs (65.8% vs 92.2%, respectively, Po0.001), patients treated
with NACT (45.0% vs 62.2%, respectively, P¼0.018), advanced
pathological T stage (pT3,4) (58.3% vs 73.3%, respectively,
P¼0.029), large number (X4) of pathologically positive lymph
nodes (21.7% vs 44.4%, respectively, P¼0.001), and advanced
pathological stage (pStage III/IV) (45.0% vs 70.0%, respectively,
P¼0.0045). On the other hand, there were no significant
correlations among CK18 expression and other parameters listed
in Table 3, such as age, gender, tumour location, and clinical
response to NACT.
Similarly, compared with CK8-negative tumours, the proportion
of CK8-positive cases was significantly higher among moderately
poorly differentiated OSCCs (65.6% vs 94.1%, respectively,
Po0.001), patients treated with NACT (46.4% vs 61.2%, respec-
tively, P¼0.0485), and large number (X4) of pathologically
positive lymph nodes (25.6% vs 40.0%, respectively, P¼0.0340).
On the other hand, there were no significant correlations among
CK8 expression and other parameters listed in Table 3, such as age,
gender, tumour location, pT, pStage, and clinical response to
NACT.
Survival rates
Disease recurrence after curative resection was diagnosed in 90
(45.2%) of 199 patients with curative resection (R0) and the mean
time to recurrence was 8.8 months. Deaths because of primary
cancer occurred in 83 (39.5%) of the 210 patients and the mean
time between surgical resection and death was 15.3 months. The
5-year DFS and OS rates for all patients were 51.6% and 54.0%,
respectively. Patients with CK18-positive tumours had significantly
poorer DFS and OS than those with CK18-negative tumours
(5-year DFS: 30.6% vs 65.8%, respectively, Po0.001, 5-year OS:
32.8% vs 68.4%, respectively, Po0.001) (Figure 4A). CK8-positive
tumours were also significantly associated with poorer DFS and OS
than CK8-negative ones (5-year DFS: 40.0% vs 59.0%, respectively,
P¼0.043, 5-year OS: 39.6% vs 63.9%, respectively, P¼0.017)
(Figure 4B). There was significant prognostic difference in survival
between CK18-positive and -negative groups according to pStage II
(5-year DFS: 33.6% vs 70.6%, respectively, P¼0.033) and pStage
III (5-year DFS: 27.8% vs 67.9%, respectively, P¼0.006), but not at
pStage I (5-year DFS: 100% vs 92.3%, respectively, NS) or pStage
IV (5-year DFS: 18.2% vs 35.0%, respectively, P¼0.579)
(Figure 4C).
Univariate analysis using Cox’s proportional hazard model
showed that the following parameters correlated significantly with
DFS: pT stage, number of pathologically positive lymph nodes (pN
number), lymphatic invasion (ly), venous invasion (v), CK18
expression, and CK8 expression (Table 4). Finally, the above
parameters were entered into multivariate analysis. The results
showed that pT, pN number, and CK18 expression significantly
and independently influenced prognosis (i.e., DFS) (HR¼1.909,
P¼0.020; HR¼2.095, P¼0.001; and HR¼1.879, P¼0.004,
respectively, Table 4).
Cytokeratin 18 expression in preoperative biopsy
specimens
In 83 patients, fiberscopic biopsy samples obtained before
treatment, which included 2–5 tissue pieces in each patient, were
also investigated for CK18 expression. Immunostaining for CK18
was basically similar among the obtained tissue pieces. Immuno-
staining showed CK18 expression in 47 (56.6%) cases (Figure 1I).
The classification of CK18 immunostaining matched that of
surgical specimens in 67 (80.7%) cases. Survival analysis also
showed that pretreated CK18-positive tumours were also
significantly associated with poorer OS than biopsy CK18-negative
ones (5-year OS: 30.4% vs 62.2%, respectively, P¼0.045) (Figure 5).
DISCUSSION
This study showed positive immunoreactivity to CK18 and CK8 in
42.9% and 40.5% of the surgical samples of OSCC, with a high
concordance rate of IHC classification (82.4%). Positive CK18 and
CK8 expression was significantly associated with pathological
factors related to tumour progression (advanced pT, large pN
number, and advanced pStage) and malignant phenotype (poor
differentiation). CK18, in particular as a single marker, was
identified as an independent prognostic predictor for DFS and OS
and to influence prognosis especially in patients with pStage II/III
tumours. The prognostic significance of CK18 expression was also
confirmed in pretreatment biopsy samples, suggesting its potential
suitability for clinical application in the future. To our knowledge,
this is the first report that has identified CK18 and CK8 expression
as a single predictor of progression and poor prognosis in OSCC
patients after curative resection.
Cytokeratins are intermediate filaments and typical epithelial
cell markers are expressed in organ-specific and differentiation-
dependent manners (Kurokawa et al, 2006). Cytokeratin filaments
are formed by tetrameric heteropolymers of two different types of
CKs (types I and II) (Chu et al, 1993). With respect to their relation
with cancer, the expression levels of some CKs, such as CK19, are
abundant and stable among tumours, therefore these molecules are
considered useful markers for micrometastases or speculation on
occult primary cancer (Fujita et al, 2006; Liu et al, 2008). On the
other hand, CK expression levels are reported to change
dynamically with carcinogenesis, at least in some cases. Such
changes include loss of CK7 and acquisition of CK20 in colorectal
carcinoma (Park et al, 2002), acquisition of CK7 and loss of CK20
in gastric carcinoma (Park et al, 2002; Kim et al, 2004), or
acquisition of CK 1, 5, 6, 8, 19 in squamous cell carcinoma
(Xu et al, 1995; Chu and Weiss, 2002b; Ikeda et al, 2008).
Furthermore, these changes correlated with malignant transforma-
tion or metastatic ability and were associated with poor prognosis
(Kim et al, 2004). Also in OSCC, earlier reports indicated that CK
expression profiles generally change along with malignant changes
(Grace et al, 1985; Lam et al, 1995; Takahashi et al, 1995; Viaene
and Baert, 1995; Chung et al, 2006), including induction of CK8,
14, 15, 17, 18, 19 expression (Grace et al, 1985; Lam et al, 1995;
Takahashi et al, 1995) and loss of CK4, 5, 13 expression (Franke
et al, 1981; Banks-Schlegel and Harris, 1984; Takahashi et al, 1995).
Among the CKs, we evaluated CK8 and CK18 in this study.
Accumulation of CK8/18 proteins was observed in about 25% of
the cases with dysplasia and half with OSCC, whereas normal
squamous epithelium of oesophagus showed no such expression.
Thus, CK8/18 expression is considered to be associated with
tumour malignancy based on the finding of increased frequency of
expression with tumour staging and correlation with unfavourable
prognosis. A similar trend was also reported in other malignancies
such as head and neck carcinoma (Gires et al, 2006), oral cavity
carcinoma (Fillies et al, 2006), and transitional carcinoma of the
urinary tract (Schaafsma et al, 1990). In contrast, some CK8/18-
expressing adenocarcinomas show downregulation of such
expression with progression, which correlates with poor outcome,
as reported in human breast cancer (Takei et al, 1995; Schaller
et al, 1996; Woelfle et al, 2004) and colorectal cancer (Knosel et al,
2006).
What are the functions of CK8/18 proteins? Although the exact
roles of these proteins are unknown at this stage, there is evidence
to suggest their involvement in invasive or growth properties of
tumours (Chu et al, 1993; Raul et al, 2004) and drug resistance
(Bauman et al, 1994; Ma et al, 2009). In vitro analysis using CK8/18
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stransfection technique showed conflicting results. In one study,
mouse L cells transfected with CK8/18 showed enhanced migration
and invasion abilities (Chu et al, 1993) whereas in another study
transfection of CK18 gene in human breast cancer cells caused
marked regression of malignancy (Buhler and Schaller, 2005).
Another possibility of the functional roles of these proteins,
CK8/18 expression levels may not directly correlate with malignant
transformation, but change accompanying with other malignant
signals, for example, epithelial–mesenchymal transition (Knosel
et al, 2006). As recent evidence showed that oncogenes activating
Ras signal-transduction pathways stimulate the expression of CK8
and CK18 genes through transcription factors, such as members of
the AP1 (Jun, Fos) and ETS families (Oshima et al, 1996), the
expression of CK8/18 may reflect integrated transcriptional
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P<0.0001
CK8 negative (n=120)
CK8 positive (n=79)
P=0.0431
CK8 negative (n=125)
CK8 positive (n=85)
P=0.0166
CK18 positive (n=5)
CK18 negative (n=13)
P=NA
pStage I
pStage III pStage IV
CK18 negative (n=53)
CK18 positive (n=22)
P=0.0334
pStage II
CK18 negative (n=28)
CK18 positive (n=31)
P=0.0061
CK18 negative (n=21)
CK18 positive (n=26)
P=0.5786
Figure 4 Survival rates according to CK18 and CK8 expression. (A, B) Disease-free survival curves (left, n¼199) and overall survival curves (right,
n¼210) classified by CK18 (A) and CK8 (B) expression for all patients were plotted by Kaplan–Meier method. (C) Disease-free survival curves classified by
CK18 expression in each pathological stage. Differences between the two groups were evaluated by the log-rank test.
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sactivation of such transcription factors. In this study, there was a
strong correlation between the expression of CK8 and CK18 with
regard to both protein accumulation and mRNA level, which could
indicate that CK8 and CK18 are regulated by some common
signals. Further investigation is necessary to explore the regulatory
mechanisms of CK8 and CK18 expression.
Survival analyses based on pathological stage by TNM
classification (Sobin, 2002) were comparable to those of earlier
reports of OSCC in Japan. In this study, CK18 had a significant
prognostic value especially in patients with pStage II/III tumours,
but not with pStage I/IV OSCCs. This finding suggests that the
prognosis of patients with pStage II/III tumours is affected by
malignant potentiality whereas that of pStage I/IV tumours is
rather influenced by anatomical staging. Therefore, for the
prediction of prognosis of patients with pStage II/III tumours, it
might be useful to integrate CK18 expression level evaluation into
pathological TNM classification.
With regard to the treatment strategies of OSCC patients, the use
of CK18 expression and pathological TNM classification (Sobin,
2002) could be a valuable guide in decision making regarding
adjuvant therapy. For example, postoperative chemotherapy might
be useful for CK18-expressing pStage II/III tumours and pStage IV
tumours regardless of CK18 expression, but not for pStage I
tumours and CK18-negative pStage II/III tumours. Furthermore,
because neo-adjuvant treatment has recently become the standard
of care for patients with advanced OSCC, evaluation of pretreat-
ment biopsy specimens is important. Our results indicated that
though CK18 protein expression varied among OSCC, it was
abundant and stable in each OSCC; oesophageal squamous cell
epithelium is intrinsically negative for CK8/18 expression and
almost all cancer tissue specimens positive for CK8/18 expression
contained more than 50% immuno-positive cells relative to the
total number of cancer cells, though in a few cases CK8/18-positive
cells constituted only 10–50% of cancer cells. On the other hand,
among CK8/18-positive cases, survival of patients with more
frequent (more than 75%) expression of CK8/18 tended to show
poorer prognosis but with no significant difference. Thus, our
classification can be considered both practical and useful, and
evaluation in biopsy specimen well represented the characteristic
of the whole tumour. Usage of biopsy specimen would highly
enhance the application of this molecule in clinical activity; as
clinical staging can be performed precisely following recent
advances in imaging modalities, it is possible that decisions
regarding selection of neo-adjuvant therapy are based in
the future on clinical TNM staging and CK18 expression level in
pretreatment biopsy specimens. It should be noted that this study
was based on analysis of squamous cell carcinoma, which is the
dominant histopathological type in East Asian countries. There-
fore, our results are not applicable to adenocarcinomas of
the oesophagus, which is the major histopathological type in
Western countries, which are characterised by overexpression of
CK8 and CK18.
In conclusion, the results of this study showed that CK18
and CK8 expression as determined by IHC could be potentially a
useful predictor of prognosis of OSCC patients after curative
resection. These results may lead to the design of new treatment
strategies for OSCC based on manipulation of CK18 and CK8
expression.
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